Platelet Function, Thrombosis
Conditions
Brief summary
This study evaluates the responsiveness of the Platelet Function Analyzer (PFA-100) to the effect of energy drinks on platelet function. Participants' will have blood drawn prior to and 60 minutes after ingesting 250ml of a commercially available sugar-free energy drink.
Detailed description
Two previous studies have demonstrated increased platelet aggregation 60 minutes after drinking a commercially available sugar-free energy drink. These studies utilized traditional platelet function studies, such as light transmission aggregometry (LTA), where platelet function is examined while adding varying concentrations of a panel of agonist to platelets. These studies are technically difficult, time intensive studies requiring specialized laboratories. They are relatively non-physiologic and do not mimic platelet response to vessel wall damage. Other tests better represent the reactions to vessel wall damage, including the PFA-100, which measures platelet aggregation and adhesion under conditions of high shear. Overall, PFA-100 is less expensive, requires less technical skill, and is less time consuming than LTA. It has been utilized in bleeding disorders and is demonstrating promise as a marker of thrombophilia. PFA-100 has demonstrated sensitivity to drug and dietary effects. It has also shown differences in closure time between sedentary and athletic individuals PFA-100 has not been used to investigate the effect of energy drinks.
Interventions
DEVICEPFA-100
The PFA-100 will be used to assess platelet function before and after energy drink consumption.
Sponsors
St. Louis University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
* a history of consuming at least one energy drink beverage in the past 6 months without adverse effects; * engage in moderate to strenuous physical activity more than 3 days per week.
Exclusion criteria
* Known thromboembolic risk including protein C or S deficiency, anti-thrombin III deficiency, Factor V Leiden; * history of thromboembolic event; * current or previous anti-coagulation therapy, anti-platelet therapy, calcium antagonists; - current tricyclic antidepressant therapy, current selective serotonin re-uptake inhibitor therapy; antibiotic therapy; or famotidine therapy; * acute illness; * pregnancy; * hemophilia; * significant history of cardiovascular disease and/or diabetes mellitus; * history of adverse effect of energy drinks. * Inability to comply with pre-test dietary and activity requirements.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Closure time | one hour | Agonist induced platelet activation and aggregation resulting in occlusion of the aperture and cessation of blood flow termed the closure time |
Secondary
| Measure | Time frame |
|---|---|
| blood pressure | one hour (every 15 minutes) |
| pulse | one hour (every 15 minutes) |
Countries
United States
Outcome results
None listed